Indian Pharma market to grow to US$ 130 bn by 2030: Gowda
The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.
The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.
The company posted net profit of Rs.7.61 crores for the period ended December 31, 2019.
The company posted net loss of Rs. 55.51 crores for the period ended December 31, 2019.
The company posted net profit of Rs.62.17 crores for the period ended December 31, 2019.
Tavaborole Topical Solution, 5%, is an oxaborole antifungal.
The company posted net profit of Rs.203.38 crores for the period ended December 31, 2019.
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
The company's business in India geography posted strong growth during the quarter as it grew by 20% on a y-o-y basis and registered revenues of Rs. 1,643 crore.
The company has posted net profit of Rs.397.06 crores for the 9 months period ended December 31, 2020.
The company posted net loss of Rs. 661.16 crores for the period ended December 31, 2019.
Subscribe To Our Newsletter & Stay Updated